MDT

101.85

+2.05%↑

A

139.48

+1.36%↑

VEEV

222.48

+1.7%↑

HQY

87.09

+2.94%↑

NEOG

9.97

+3.96%↑

MDT

101.85

+2.05%↑

A

139.48

+1.36%↑

VEEV

222.48

+1.7%↑

HQY

87.09

+2.94%↑

NEOG

9.97

+3.96%↑

MDT

101.85

+2.05%↑

A

139.48

+1.36%↑

VEEV

222.48

+1.7%↑

HQY

87.09

+2.94%↑

NEOG

9.97

+3.96%↑

MDT

101.85

+2.05%↑

A

139.48

+1.36%↑

VEEV

222.48

+1.7%↑

HQY

87.09

+2.94%↑

NEOG

9.97

+3.96%↑

MDT

101.85

+2.05%↑

A

139.48

+1.36%↑

VEEV

222.48

+1.7%↑

HQY

87.09

+2.94%↑

NEOG

9.97

+3.96%↑

Search

IQVIA Holdings Inc

Open

SectorGezondheidszorg

239.25 -0.11

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

238.96

Max

242.79

Belangrijke statistieken

By Trading Economics

Inkomsten

66M

332M

Verkoop

83M

4.1B

K/W

Sectorgemiddelde

32.693

89.037

Winstmarge

8.098

Werknemers

91,000

EBITDA

102M

883M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+10.54% upside

Dividenden

By Dow Jones

Volgende Winsten

5 feb 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

3B

40B

Vorige openingsprijs

239.36

Vorige sluitingsprijs

239.25

Nieuwssentiment

By Acuity

50%

50%

177 / 360 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

IQVIA Holdings Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

21 jan 2026, 23:49 UTC

Belangrijke Marktbewegers

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

21 jan 2026, 21:12 UTC

Belangrijke Marktbewegers

Automaker Stocks Rise After Trump Calls Off European Tariffs

21 jan 2026, 21:00 UTC

Acquisities, Fusies, Overnames

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

21 jan 2026, 20:29 UTC

Belangrijke Marktbewegers

Chip Makers Gain After Trump Calls Off European Tariffs

21 jan 2026, 20:04 UTC

Belangrijke Marktbewegers

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

21 jan 2026, 23:48 UTC

Marktinformatie

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

21 jan 2026, 23:34 UTC

Marktinformatie

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

21 jan 2026, 22:39 UTC

Winsten

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

21 jan 2026, 21:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

21 jan 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

21 jan 2026, 21:35 UTC

Acquisities, Fusies, Overnames

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

21 jan 2026, 21:19 UTC

Winsten

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

21 jan 2026, 20:45 UTC

Acquisities, Fusies, Overnames

Deutsche Borse Group to Acquire Allfunds for $6.19B

21 jan 2026, 20:36 UTC

Marktinformatie

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

21 jan 2026, 20:31 UTC

Marktinformatie

Oil Settles Higher With Support From Heating Fuel -- Market Talk

21 jan 2026, 20:27 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

21 jan 2026, 20:27 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

21 jan 2026, 20:27 UTC

Marktinformatie

Was It a 'TACO' Event? -- Market Talk

21 jan 2026, 20:26 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

21 jan 2026, 20:23 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

21 jan 2026, 20:21 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

21 jan 2026, 20:19 UTC

Acquisities, Fusies, Overnames

Deutsche Boerse Group Agrees to Buy Allfunds

21 jan 2026, 20:08 UTC

Winsten

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

21 jan 2026, 20:03 UTC

Marktinformatie

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

21 jan 2026, 19:51 UTC

Marktinformatie

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

21 jan 2026, 19:43 UTC

Marktinformatie

U.S. Ethanol Production Expected to Slip -- Market Talk

21 jan 2026, 19:31 UTC

Marktinformatie

Gold Settles at Fresh All-Time High -- Market Talk

21 jan 2026, 19:24 UTC

Winsten

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21 jan 2026, 19:10 UTC

Marktinformatie

Mexican Inflation Seen Picking Up in Early January -- Market Talk

21 jan 2026, 18:57 UTC

Marktinformatie

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Peer Vergelijking

Prijswijziging

IQVIA Holdings Inc Prognose

Koersdoel

By TipRanks

10.54% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 258.31 USD  10.54%

Hoogste 290 USD

Laagste 215 USD

Gebaseerd op 15 Wall Street-analisten die 12-maands prijsdoelen bieden voor IQVIA Holdings Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

15 ratings

12

Buy

3

Hold

0

Sell

Technische score

By Trading Central

150.68 / 153.45Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Neutral Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

177 / 360 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
help-icon Live chat